BIOEOTCPharmaceutical PreparationsFiscal year ends December 31

Bio Essence Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.42+0.03 (+7.72%)

Close on Oct 19, 2026

Market cap: $21.38M
P/E (TTM): 10.5
Dividend yield: –

Bio Essence Corp cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	0.00	0.00	0.00	0.01	0.04	0.03
Stock-Based Compensation	–	–	–	–	–	0.01
Deferred Income Taxes	–	–	–	0.00	0.00	–
Change in Accounts Receivable	-0.02	-0.01	-0.01	0.00	0.02	-0.02
Change in Inventory	–	–	-0.01	0.03	0.06	0.26
Change in Accounts Payable	0.03	0.01	-0.01	-0.02	0.01	-0.03
Operating Cash Flow	1.57	0.62	-1.03	-0.70	-1.29	-0.73
Capital Expenditures	–	–	0.00	0.00	-0.12	-0.01
Acquisitions	–	0.00	–	–	–	–
Sale of Property, Plant & Equipment	–	–	–	–	0.00	–
Investing Cash Flow	–	0.00	-0.09	-0.06	-0.12	-0.01
Stock Issued	–	–	–	–	–	-0.10
Debt Repaid	–	0.00	0.00	-0.01	0.00	–
Financing Cash Flow	-1.57	-0.62	1.11	0.77	1.41	0.73
Net Change in Cash	–	–	–	0.01	-0.01	–
Free Cash Flow	–	–	-1.03	-0.71	-1.41	-0.74
Income Taxes Paid	0.00	0.00	0.00	0.00	0.00	0.00
Interest Paid	0.00	0.01	0.02	0.01	0.04	0.04

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.7%
Operating margin: 52.9%
Net margin: 52.1%
Return on equity, FY2025: -35.5%

Financial strength

Current ratio: 0.38
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.0%

Valuation

P/E ratio: 10.5
Price to sales: 7.34
Price to book: 9.13
Dividend yield: –